ArticleJournal of veterinary internal medicine
Apoptosis Inhibitor of Macrophage (CD5-Like Antigen) in Healthy Dogs and Dogs With Acute Kidney Injury.
Article in Journal of veterinary internal medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundApoptosis inhibitor of macrophage (AIM) is a fundamental mediator of recovery from acute kidney injury (AKI) in mice, but its role in AKI in dogs is unknown. HYPOTHESIS/
objectivesTo detect and quantify AIM in serum and urine from both healthy dogs and dogs with AKI, and to determine if AIM is higher in dogs with AKI compared to healthy controls. ANIMALS: Eight dogs with International Renal Interest Society (IRIS) Grade II-V AKI and 10 healthy adult dogs.
methodsRetrospective case-control study. Liquid chromatography-mass spectrometry (LC-MS) based targeted proteomics was used to quantify AIM. AIM peak areas were compared between the AKI and healthy cohorts and correlated with selected markers of renal function.
resultsAIM was able to be quantified in the urine of 5/8 dogs with AKI and 1/10 healthy dogs. AIM was quantified in the serum of all dogs, and there was no difference in peak area between the two groups (AKI: median, 67 840 (range, 9797-98 725); control: median, 79 072 (range, 46 400-160 330); p = 0.274). In dogs with AKI, AIM was not correlated with serum creatinine, blood urea nitrogen, phosphorus, or potassium concentrations, urine specific gravity, or IRIS AKI grade. CONCLUSIONS AND CLINICAL IMPORTANCE: AIM was predominantly detected in the urine of dogs with AKI and not in the urine of healthy dogs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.